Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in XXXX .

@entity1 @entity8958 @entity470 @entity984 @entity957 @entity2 @entity5 @entity406 @entity876 @entity982 @entity31082 @entity2250 @entity420 @entity2839
BACKGROUND: The clinical implementation of genomic profiling for @entity2 with high-throughput, multiplex tests is warranted to allow prioritization of appropriate therapies for individual @entity1 . We have now applied such testing to detect actionable mutations that may inform treatment recommendations in @entity2 . @entity1 AND METHODS: We prospectively applied amplicon sequencing panels that cover both mutational hotspots in 22 genes related to lung and colon tumorigenesis as well as 72 major variants of ALK, @entity8958 , @entity31082 , and @entity2250 fusion transcripts. We then determined the proportion of @entity1 who received genotype-directed therapy and their overall survival (OS). RESULTS: Tumor specimens from 110 @entity1 with @entity2 recruited between July 2013 and March 2015 were analyzed. The most common genetic alterations were @entity876 mutations in 42 @entity1 , followed by @entity470 mutations in 25, @entity2839 mutations in 12, and @entity984 mutations in 10. Potentially actionable mutations were identified in 44 @entity1 including 50% of those with @entity420 and 14% of those with @entity957 . The OS of @entity1 with advanced or recurrent @entity5 who had an actionable mutation and received targeted therapy (median OS not achieved) was significantly longer than that of those with no mutation (18.1 months, P = 0.041) or of those with a mutation not so treated (6.1 months, P = 0.0027). CONCLUSIONS: Multiplex genomic testing was performed on @entity406 -fixed, @entity982 -embedded @entity5 specimens with a success rate of >= 95%. Such testing can assist physicians in matching @entity1 with approved or experimental targeted treatments. CLINICAL TRIAL REGISTRATION: The University Medical Hospital Information Network (UMIN) Clinical Trials Registry under the identifier UMIN000014782.
